Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Instil Bio

Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
From Instil Bio
Via GlobeNewswire
Tickers TIL
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
From Instil Bio
Via GlobeNewswire
Tickers TIL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.